|
FY2023 OUTLOOK |
||
|
On track towards full-year FY2023 Management Guidance |
||
|
(Billion yen except per share amounts) |
FY2023 FORECAST (Unchanged from October 2023) |
FY2023 MANAGEMENT GUIDANCE Core Change at CER (Non-IFRS) (Unchanged from May 2023) |
|
Revenue |
3,980.0 |
|
|
Core Revenue |
3,980.0 |
Low-single-digit % decline |
|
Reported Operating Profit |
225.0 |
|
|
Core Operating Profit |
1,015.0 |
Low-10s % decline |
|
Reported Net Profit |
93.0 |
|
|
Reported EPS (yen) |
59 |
|
|
Core EPS (yen) |
447 |
Low-20s % decline |
|
Free Cash Flow* |
400.0-500.0 |
|
|
Annual Dividend per Share (yen) |
188 |
|
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
